Inclusion Criteria:

          -  Pathologically confirmed stage IIIB, IV non-squamous non-small cell lung cancer, with
             measurable lesions (the long axis of tumor lesions ≥ 10mm with CT, the short axis of
             lymph node lesions ≥ 15mm with CT, the lesions not receive radiotherapy, frozen or
             other local treatment);

          -  Patients with slow progression on first-line EGFR TKI(erlotinib / icotinib /
             gefitinib) treatment;

          -  No T790M mutation including an assessment from tumor biopsy obtained while on or
             subsequent to the most recent EGFR TKI therapy;

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2;

          -  Life expectancy of more than 3 months;

          -  Adequate bone marrow function: WBC ≥ 3.0 ×10 E+9/L, neutrophil ≥ 1.5 × 10 E+9/L,
             platelets ≥ 80 × 10E+9/L,Hb ≥ 10.0g/dL;a total bilirubin (TBil) of ≤1.5 upper normal
             limitation (UNL), a alanine aminotransferase (ALAT) and aspartate aminotransferase
             (ASAT) of ≤3UNL or ≤5UNL in case of liver metastasis, a creatinine (Cr) of ≤ 1.5 UNL;
             a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault);

          -  Female subjects of child-bearing potential must agree to use contraceptive measures
             starting 1 week before the administration of the first dose of apatinib until 8 weeks
             after discontinuing study drug. Male subjects must agree to use contraceptive measures
             during the study and 8 weeks after last dose of study drug;

          -  the participants volunteered to join this study should sign the informed consent
             forms, have better compliance in the follow-up;

        Exclusion Criteria:

          -  Squamous cell carcinoma (including adenosquamous carcinoma); Small cell lung carcinoma
             (including small cell carcinoma and non-small cell mixed lung carcinoma);

          -  Active brain metastases, cancerous meningitis, patients with spinal cord compression;

          -  Rapid progression of the disease or cancer invades vital organs;

          -  The distance between the tumor lesion and the large blood vessel is less than 5 mm, or
             there is a central tumor invading local macrovascular;

          -  obvious pulmonary cavity or tumor necrosis;

          -  Uncontrollable high blood pressure;

          -  Grade Ⅱ or above myocardial ischemia or myocardial infarction or arrhythmia control is
             not good,Ⅲ ~ Ⅳ grade cardiac insufficiency, or cardiac ultrasonography showed left
             ventricular ejection fraction (LVEF) <50% according to the NYHA standard;

          -  Have a history of interstitial lung disease or patients with interstitial lung
             disease;

          -  Coagulation abnormalities (INR> 1.5 or PT> ULN + 4s or APTT> 1.5 ULN) with bleeding
             tendency or undergoing thrombolytic or anticoagulant therapy;

          -  There was significant hemoptysis within 2 months prior to enrollment, or a daily
             hemoptysis volume is 2.5 ml or above;

          -  A clinically significant bleeding symptom or bleeding tendencies such as
             gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above,
             or vasculitis that occurred within 3 months prior to enrollment;

          -  Aneurysm / venous thrombotic events such as cerebrovascular accident (including
             transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein
             thrombosis and pulmonary embolism;

          -  Arterial / venous thrombotic events such as cerebrovascular accidents (including
             transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein
             thrombosis and pulmonary embolism within 12 months prior to enrollment;

          -  Hereditary or acquired bleeding and thrombophilia, such as hemophilia, coagulopathy,
             thrombocytopenia, hypersplenism；

          -  Long-term unhealed wounds or fractures;

          -  Major surgery or severe traumatic injury, fracture or ulcer within 4 weeks prior to
             enrollment;

          -  Unable to swallow, chronic diarrhea or intestinal obstruction;

          -  Abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months
             prior to enrollment;

          -  Urinary protein ≥ ++, 24-hour urinary protein ≥ 1.0 g;

          -  Active infections require antimicrobial treatment;

          -  ALK gene abnormalities (gene fusion or mutation occurred);

          -  Pregnant or lactating women, or women unwilling or unable to take effective
             contraception;